Антагонисты минералокортикоидных рецепторов в лечении больных с сердечной недостаточностью после инфаркта миокарда и с хронической сердечной недостаточностью
- Авторы: Терещенко СН1, Жиров ИВ1, Осмоловская ЮФ1
-
Учреждения:
- ФГБУ РКНПК Минздрава России, Москва
- Выпуск: Том 85, № 12 (2013)
- Страницы: 137-143
- Раздел: Передовая статья
- URL: https://journals.rcsi.science/0040-3660/article/view/31414
- ID: 31414
Цитировать
Полный текст
Аннотация
Аннотация. Антагонисты минералокортикоидных рецепторов спиронолактон и эплеренон стали частью стандартной медикаментозной терапии у больных с сердечной недостаточностью (СН). В рандомизированных клинических исследованиях показана клиническая эффективность спиронолактона и эплеренона, приводящих к снижению смертности больных с систолической СН. Остаются открытыми вопросы об эквивалентности этих двух препаратов и их способности оказывать положительное влияние у больных с клинически проявляющейся СН, включая хроническую СН с сохраненной систолической функцией левого желудочка.
Полный текст
Открыть статью на сайте журналаОб авторах
С Н Терещенко
ФГБУ РКНПК Минздрава России, Москва
И В Жиров
ФГБУ РКНПК Минздрава России, Москва
Ю Ф Осмоловская
ФГБУ РКНПК Минздрава России, Москва
Email: yuliaosm@mail.ru
Список литературы
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787-1847.
- McMachon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Cur Opini Pharmacol 2001; 1: 190-196.
- Weber K.T., Villarreal D. Aldosterone, and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71 (Suppl A): 3A-11A.
- Yasky J., Ledesma G.A., Tutera A., Collia L.F. A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. Pharmatherapeutica 1986; 4 (8): 480-485.
- Smith A.G. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin 1980; 7 (2): 131-136.
- Muller J. Spironolactone in the management of congestive heart failure: a rewiew. Clin Ther 1986; 9 (1): 63-76.
- Arriza J.L., Weinberger C., Cerelli G. et al. Cloning of human mineralocorticoid receptor complementory DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237 (4812): 268-275.
- Корочкин И.М., Матвеева И.В. Гормональные нарушения и лечение больных с рефрактерными формами застойной сердечной недостаточности. Кардиология 1977; 8: 36-43.
- Pierpont G.L., Francis G.S., Cohn J.N. Effect of captopril on renal function in patients with congestive heart failure. Br Heart J 1981; 46 (5): 522-527.
- Sharpe D.N., Coxon R.J. Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Phatmacol 1982; 14 (Suppl 2): 161S-167S.
- Nicholls M.G., Espiner E.A., Ikram H. et al. Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. J Clin Endocrinol Metab 1981; 52 (6):1253-12536.
- Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82 (5): 1730-1736.
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23): 1429-1435.
- Staessen J., Lijnen P., Fagard R. et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91 (3): 457-465.
- Borghi C., Boschi S., Ambrosioni E. et al. Evidence of a partial escape of reninangiotensine-aldosterone blocade in patients with acute myocardial infarctiontreated with ACE inhibitors. J Clin Pharmacol 1993; 33 (1): 40-45.
- Lee A.F., MacFadyen R.J., Struthers A.D. Neurohormonal reactivationin heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1 (4): 401-406.
- Мареев В.Ю., Скворцов А.А., Челмакина С.М. и др. Способны ли ингибиторы АПФ эффективно контролировать активность ренин-ангиотензин-альдостероновой системы при длительном лечении хронической сердечной недостаточности? Кардиология 1999; 2: 27-34.
- Urata H., Healy B.H., Stewart R. et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990; 66 (4): 883-390.
- Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monographs on Endocrinology. 2nd ed. N.Y.: Springer-Verlag 1988.
- MacFadyen R.J., Lee A.F., Morton J.J. et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82 (1): 57-61.
- Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13-21.
- Мареев В.Ю., Скворцов А.А. Блокада эффектов альдостерона у больных сердечной недостаточностью: современный взгляд на проблему - эплеренон (часть II). Сердеч недостат 2011; 4: 222-227.
- Pitt B., Zannand F., Remme W. et al. The effect of spirinilactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
- Delyani J., Myles K., Funder J. et al. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
- Cook C.S., Berry L.M., Kim D.H. et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002; 30 (12): 1344-1351.
- Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15 (8): 709-716.
- Sadee W., Dagcioglu M., Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 1973; 185 (3): 686-695.
- Pitt B., Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose-finding study in patients with heart failure. J Am Coll Cardiol 1999; 33: 188A-189A.
- Degasparo M., Joss U., Ramjoue А. et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-656.
- Zannad F., McMurray J.J.V., Drexler H. et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617-622.
- Zannad F., McMurray J.J.V., Krum H. et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms N Engl J Med 2011; 364: 11-21.
- Swedberg K., Zannad F., McMurray J.J. et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598-1603.
- Pitt B., Remme W., Zannad F. et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348: 1309-1321.
- Mottram P.M., Haluska B., Leano R. et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110 (5): 558-565.
- Mak G.J., Ledwidge M.T., Watson C.J. et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54 (18): 1674-1682.
- Edwards N.C., Ferro C.J., Kirkwood H. et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010; 106 (10): 1505-1511.
- Deswal A., Richardson P., Bozkurt B., Mann D.L. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17 (8): 634-642.
- Edelmann F.W.R., Schmidt A.G. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309 (8): 781-791.
- Desai A.S., Lewis E.F., Li R. et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162 (6): 966-972.
- Guichard J., Clark D. II, Calhoun D.A. et al. Aldosterone receptor antagonists: current perspectives and therapies. Vascular Health and Risk Management 2013; 9: 321-331.
- http://www.clinicaltrials.gov/ct2/show/NCT01176968?term=aldosterone+and+reminder&rank=1
- http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_458235.pdf